InFierce PharmaPublished2024Year Pharmaceutical EnterpriseChief Executive Officer (CEO）In the compensation rankings, both the rankings and compensation structures have seen significant changes.Multiple large-scale mergers and acquisitions and substantial stock option gains for severalCEOBrought extremely rich returns. Most notably,BioNTechCo-Founder and CEOUğur ŞahinSeagen Surpasses Johnson & Johnson with a Gain of Several Hundred Million Dollars from Stock OptionsCEO Joaquin DuatoThe record of蝉联.

Source: Maryam-Daneshpour

Eli Lilly and CompanyCEO David RicksThen, relying on the excellent sales performance of the tirzepatide series products, with2920Million-dollar salary ranks second. More surprisingly, according toStatMedia reports suggest that its actual total revenue may be close to1.14Billion US dollars.

PfizerCEO Albert BourlaIn2460Million USD in compensation ranks third, increasing from the previous year.14%. This growth is attributed to its leading role in completing the acquisition ofADCLeading enterprise in the fieldSeagenUp to430The strategic acquisition worth billions of dollars is closely related, which significantly enhances Pfizer's layout and competitiveness in the field of oncology treatment.

Following closely are Johnson & Johnson, Amgen, Gilead, Merck, AstraZeneca,VertexAndBMSTheCEO`, whose annual salary exceeds`1880Million USD.

BioNTech CEO 

Uğur Şahin

2024 Compensation: $287 Million

Year-on-Year Change: Increased by 8448%

In 2024,Şahin exercised its stock options, purchased the corresponding shares, and thus received a total compensation of 265 million euros (approximately 287 million US dollars).This amount is much higher than the €3.1 million (approximately $3.35 million) it received in 2023,Nearly ten times the average compensation of executives at other biopharmaceutical companies.

The option plan dates back to 2019, when the companyŞahinGranted large stock options, such incentive tools are typically used to retain core talent, allowing employees to purchase a certain number of company shares at a preset price after meeting vesting conditions.

According to BioNTech's annual report released in 2020, the company agreed to grantŞahinOptions to purchase 4,374,963 shares of common stock. Although these options became exercisable in 2023,ŞahinNot exercised until August 2024.

In this options arrangement,ŞahinThe exercise price was 13.74 euros per share (approximately 15 US dollars). On the exercise date, the closing price of BioNTech reached 73.68 euros per share. The difference between the two made the "intrinsic value" of the purchased shares amount to approximately 259.5 million euros (approximately 281 million US dollars).

CEO of Eli Lilly David Ricks

2024 Compensation: $29.2 Million

Year-on-Year Change: Increased by 10%

David RicksThe total compensation for 2024 is2920Million USD, compared to2023Year's2660Million USD Increase10%. Since2017Year of taking officeCEOSince then, its salary level has continued to rise, from the initial1580Million US dollars has gradually increased to date.

This growthMainly benefiting from Eli Lilly and Company'sGLP-1Class of Hypoglycemic and Lipid-Reducing Drugs:Tirzepatide Series Products（MounjaroAndZepbound）Strong sales performance. In 2024, the series of drugsTotal sales reached up to164USD billion, driving Lilly's overall revenue growth32%, reaching450Billion US dollars.

In addition,2024Non-metabolic drugs from Eli Lilly achieved20%The growth was equally remarkable, particularly in breast cancer therapies.VerzenioAnd Heart Failure DrugsJardianceRespective Contributions53Billion US dollars and33Billion dollars in sales.

Under his leadership, the Alzheimer's disease monoclonal antibody drug Kisunla finallyEbglyss has been approved, and at the same time, Ebglyss has also received FDA approval for the indication of Crohn's disease.

These impressive achievements have brought him substantial rewards. His compensation mainly includes: approximately170Million USD base salary,170Million USD of pension increase,570Million USD annual bonus, and1970Million-dollar equity incentives.

Notably, the aforementioned figures fall under "awarded compensation," rather than“Actual Income”. According toStatMedia reports, if based onDavid RicksIn2024Calculation of the actual stock gains exercised and cashed out during the year,Last year's actual total revenue should be closer to1.14Billion US dollars。

CEO of Pfizer Albert Bourla

2024 Compensation: $24.6 Million

Year-on-year change: Increased by 14%

Albert Bourla in2024Total compensation received in the year is2460Million US dollars, which is the second highest in the company's annual revenue over the years, only after2022Year's3300Million USD. In terms of salary structure,Albert BourlaThe basic salary is180Million USD, stock and option awards approximately1500Million US dollars, with approximately700Million dollars from performance incentives, which constitute the main part of his compensation.

Pfizer's Compensation Committee evaluated its annual performance, stating: "InAlbert BourlaUnder the leadership of Dr.,The company is in2024Successfully advanced strategic transformation and R&D innovation within the year. The effective promotion of business progress through the reorganization of the R&D organization played a key role in implementing the five strategic priorities for the entire year.”

2024For the whole year, Pfizer achieved total revenue636Billion USD, non-COVID product business contributed12%The operational growth. The company also successfully completed40Billion-dollar cost-saving plan, and with the help of2023Year toADC LeaderSeagenThe430The acquisition for billions of dollars significantly enhanced Pfizer's market competitiveness in the field of oncology treatment.

According to the company's announcement, Pfizer launched seven pivotal studies in 2024 and is expected2025The year will see four regulatory approval decisions, completion of data reads from nine Phase III clinical trials, and the initiation of thirteen potentially pivotal R&D programs.

Johnson & Johnson CEO Joaquin Duato

2024 Compensation: $24.6 Million

Year-on-Year Change: Decreased by 14%

Joaquin DuatoIn2024Total annual compensation2460Million USD, compared to2023Year's2840Million USD has decreased. The company explained in its regulatory filings,The reduction in compensation is mainly related to the change in the estimated value of the pension.: This section in2023Annual Growth620Million US dollars, and2024Only Increase Annually270Million USD.

Specifically,Joaquin DuatoThe bonus is awarded by2023Year's440Million USD decreased to400Million USD; Equity incentives also from1600Million USD reduced to1570Million USD. Its2024Annual Performance Bonus Achievement“Target Value115%”, below2023Year's130.4%; however, the long-term incentive compensation achievement rate is130%, superior to2023Year's125%。

Nevertheless, according toEvaluation by the Johnson & Johnson Board of Directors,Joaquin DuatoPerformance"Still 'exceeded the annual target.' Under his leadership,"Johnson & Johnson Exceeds Expectations in Three Core Metrics: Operational Sales, Adjusted Operational Earnings Per Share, and Free Cash Flow。

In terms of business expansion,Joaquin DuatoIn2024Led Johnson & Johnson to complete several important acquisitions in the year, including the acquisition ofShockwave Medical（131billion US dollars),V-Wave（17Billion US dollars) andYellow Jersey（12USD billion), and within this year1Monthly completion ofIntra-Cellular（146Billion USD) Acquisition.

Amgen CEO 

Robert Bradway

2024 Compensation: $24.4 Million

Year-on-Year Change: Increased by 8%

2024Year, long-term served as the CEO of AmgenRobert BradwayRewarded again for outstanding leadership. In the thirteenth year of service, the company's performance reached a new high.

Previously, Amgen278Billion USD to complete the acquisition ofHorizon TherapeuticsThe acquisition, thereby expanding the portfolio of rare disease drugsUplizna、KrystexxaAndTepezzaIncluded in the product pipeline.This strategic move drives the company2024Annual Sales Achieved19%The growth, reaching334Billion US dollars.

Based on this performance,Robert BradwayReceived the corresponding high compensation, its2024The total amount of compensation granted in the year reached2440Million USD, compared to2023Annual Growth8%, while also setting a new record for himself since2012Annual salary record since taking charge of Amgen in the year.

Amgen's board of directors believes that,Robert BradwayWith unique insights centered on shareholder value, capable of assisting the company in efficiently executing strategies and business plans to maximize shareholder returns.。

Gilead CEO Daniel O’Day

2024 Compensation: $23.7 Million

Year-on-Year Change: Increased by 5%

Daniel O’DayIn2024Total annual compensation is2380Million US dollars, increased from the previous year5%, achieving a continuous four-year increase and setting a new record since2019A new high in compensation since he joined the company. His total compensation is approximately the company's average employee salary (24.43Million USD)97Times.

The specific composition includes:180Million USD base salary (Year-over-Year Growth)1.4%）、1650Million USD Equity Incentive,400Million USD performance bonus, and130Other compensation in millions of US dollars.

2024In the year, the company's total annual revenue increased.6%, described as“A Year of Remarkable Clinical Progress”. InDaniel O’DayUnder the leadership ofGilead inHIVThe therapeutic area continues to consolidate its advantages and steadily expand into new treatment directions.Among them, long-actingHIVDruglenacapavir（capsidInhibitors) have attracted significant attention in the industry and are expected to bring important changes to the pre-exposure prophylaxis market for HIV.

At the beginning of the same year,Gilead43Billion-dollar acquisitionCymaBay TherapeuticsAlso quickly showed results.: The primary biliary cholangitis drug it obtainedLivdelzi(OriginalCymaBayProducts under research) in2024Year8Month Obtained in the United StatesFDAApproved for marketing. The drug is from Gilead.2019The sixth innovative therapy successfully launched since, marking the company's progress towards“2030Ten Transformational Therapies Launched Before the Year”The strategic goal has been more than half achieved.

CEO of Merck & Co. Robert Davis

2024 Salary: $23 Million

Year-on-Year Change: Increased by 14%

2024Year, CEO of MerckRobert DavisThe total compensation reached2320Million US dollars, increased from the previous year13%, continued from2021Appointed inCEOwith a steadily increasing trend.

Specifically,Robert Davis2024Annual compensation includes more than160Million USD base salary,1770Million USD in equity incentives,280Million USD performance bonus, and approximately56Other compensation in millions of dollars.

Merck & Co., Inc. Officially Revealed,Company2024Annual income realized10%The growth has exceeded the targets set for revenue and pre-tax profit in the assessment of executive compensation.

However, withRobert DavisCompared with the continuous rise in compensation, the overall development of the company presents a more complex situation. DespiteKeytrudaHas grown into the world's best-selling drug, providing strong momentum for the company, but once contributed substantial profits.HPVGardasil Vaccine (Gardasil) has recently faced sales pressure in the Chinese market.

Fortunately, Merck has made significant progress in research and development, launching more than20Phase III clinical trials, and has cumulatively gained over25Regulatory approval.

In addition to internal R&D progress, Merck also advances through acquisitions.Harpoon Therapeutics、EyebiotechAnd Clon Biopharmaceuticals, further enriching its pipeline of drug candidates in the fields of oncology, ophthalmology, and immunology.

In addition, the company has also introduced through authorized licensing from Hansoh Pharma,LaNova...have obtained multiple promising drugs under research.

CEO of AstraZeneca 

Pascal Soriot

2024 Compensation: $22.9 Million

Year-on-year change: Increased by 29%

2024Year, AstraZeneca CEOPascal SoriotThe total amount of compensation granted reached1790Million pounds (approximately2290Million US dollars), increased from the previous year29%。

The increase in compensation was primarily due to the board raising the amount of their long-term performance stock awards from their base salary.650%Promoted to850%. At the same time,Pascal SoriotThe basic salary in2024Years have also increased.4%, reaching nearly150Million pounds.

Annual bonuses tied to company performance also showed growth, from2023Year's Date280Million pounds increased to nearly350Million pounds. According to the performance scorecard used by the board to evaluate their bonuses,Pascal SoriotScored full marks in both total revenue and core earnings per share, two key financial indicators.2024In the year, AstraZeneca's total annual revenue increased year-on-year.18%, reaching541Billion USD; Core EPS Growth13%, for8.21USD.

The company's multiple key tumor drugs (Tagrisso、Imfinzi、Calquence、LynparzaAndEnhertu）All achieved double-digit revenue growth.FarxigaTotal annual sales reached77Billion USD, year-on-year growth29%, becoming the company's best-selling drug.

However,The Company Failed to Meet Preset Goals in R&D Pipeline Progress and Cash FlowIn terms of the R&D pipeline, AstraZeneca has achieved progress in phase II trial initiation and advancement, new molecule project establishment, and investment decision-making for key trials related to lifecycle management.24Progress, slightly below the set27Project Target.

AstraZeneca's board commented in its remuneration report: "Despite the increasing volatility in the global environment,Pascal SoriotMr. leads AstraZeneca in2024Achieved strong performance in the year,Not only maintained significant revenue growth, but the R&D pipeline also demonstrated remarkable progress.。”

Vertex CEO 

Reshma Kewalramani

2024 Compensation: $21.54 Million

Year-on-Year Change: Increased by 4%

2024Year,VertexChief Executive OfficerReshma KewalramaniTotal Compensation Obtained2154Million USD, compared to2023Year's2059Million USD increase by approximately100Million US dollars.

Salary increase mainly comes from two parts: basic salary adjustment4.1Million USD to154Million US dollars, and the annual cash bonus increased by nearly90Million USD, reaching494.1Million USD. In addition, most of her income is reflected in the form of equity incentives, with an amount of approximately1500Million US dollars, the same as last year.

VertexFully affirmed in the public statementReshma KewalramaniUnder the outstanding leadership, demonstrating comprehensive capabilities in R&D, production, commerce, and finance, effectively executing corporate strategies, advancing the development of innovative therapies for major diseases, and successfully achieving various business objectives.She led the company to achieve sales revenue110billion dollars, a year-on-year increase of12%；And successfully promoted the launch of multiple innovative drugs, includingCRISPRGene Editing TherapyCasgevyAnd non-opioid analgesicsJournavx。

At the same time,Reshma KewalramaniAlso for the second consecutive year becameFierce PharmaYearCEOThe only female executive on the salary list, highlighting her unique position in the industry.

BMS CEO 

Chris Boerner

2024 Salary: $18 Million

Year-on-Year Change: Increased by 122%

While serving asBMSThe first full year of the CEO,Chris BoernerThe total compensation received by the PhD reached1880Million US dollars, compared to when he previously held other executive positions850Million USD achieved significant growth.

Chris BoernerIn2023Year11Officially took over as CEO in the monthGiovanni Caforio`, in charge of`BMS. The task he faces is not easy: the patents for several of the company's core drugs will expire in the coming years. To bolster the R&D pipeline,BMSIn2024Completed in the yearMirati Therapeutics、Karuna TherapeuticsAndRayzeBioThe acquisition.

Among them,In140Billion-dollar acquisitionKarunaOne of the most important achievements for the company in recent years, New Antipsychotic DrugsCobenfySuccessfully approved. In addition,BMSLast year, it was obtained globally23Item regulatory approval, exceeding the target set by the board of directors15To17Project Goals. In the compensation report, the company particularly emphasized five key R&D projects that have entered the registration phase, all focused on the oncology field.

In terms of long-term goal advancement,BMSIn total21Priority research items achieved or exceeded the execution targets, surpassing the original ones.14To16Item. According to the letter of authorization, the company also completed10Concept Validation Phase“Continue/Termination”Decision, also exceeded the board's expectations.

Unlike most pharmaceutical companies that use annual total revenue as the evaluation metric for executive compensation,BMSPay more attention to its“Increase Product Portfolio Revenue”. This part of the business in2024Annual Sales Revenue226Billion USD, compared to2023Year's194USD billion steadily increased, meeting the board's expectations. Based on the outstanding performance of this indicator,Chris BoernerThus, the full amount of the bonus was awarded.

PharmSnap Media Business Cooperation

Media PR | News &Press Release

Manager Zhang: 18600036371 (Same for WeChat)

Click "PharmSnap" below”, follow more exciting content

The push rules of WeChat Official Accounts have changed again. If you don't tap"Views"Or not set to"Star Mark", we might just dissipate in the vast sea of literature~ Click here, don't miss out on the latest news from PharmaDJ!??